• Fasting Plasma Glucose
  

• Mean changes of HbA1c, Fasting Insulin, HOMA-IR and QUICKI indices, Body weight, waist measurements, total cholesterol, LDL-C, HDL-C, total/HDL, apolipoprotein A-1 & B, triglycerides, free fatty acids, hs C-reactive protein, adiponectin, edema.
  

The objectives of the study are to identify doses of PPM-204 that are therapeutically effective and well tolerated in improving glycemic control over 24 weeks of treatment in subjects with type 2 diabetes mellitus (T2DM).

Inclusion Criteria:

• Men and women of non-childbearing potential, 18 to 70 years old
• Subjects currently treated with diet and exercise alone and subjects receiving a single oral antidiabetic medication
• BMI > 23 and < 43
• For subjects currently treated with 1 antidiabetic medication: HbA1c is greater than or equal to 6.8% and less than or equal to 8.5%.
• For subjects not currently treated with antidiabetic medications: HbA1c is greater than or equal to 7.2% and less than or equal to 9.0%

Exclusion Criteria:

• Subjects requiring insulin therapy
• Subjects currently receiving 2 or more oral antidiabetic medications
• Subjects requiring systemic corticosteroids, unless treatment was discontinued at least 4 weeks before the screening visit
• Subjects receiving warfarin
• Subjects currently receiving thiazolidinediones, unless treatment was discontinued 8 weeks before the screening visit
• Significant diabetic complications (retinopathy, nephropathy, symptomatic neuropathy)